Sales Growth At Roche In Early 1995

14 May 1995

During the first fourth months of 1995, sales growth was strong at Roche of Switzerland. Turnover amounted to 5.1 billion Swiss francs ($4.5 billion), up 2% in Swiss francs terms or 15% when expressed in local currencies.

Sales of pharmaceuticals grew 10% in Swiss franc terms, and 25% in local currencies to 3 billion francs. The company said that there was a further increase in sales volume of the top-selling products, and an upsurge in demand for new innovative compounds.

Sales of vitamins and fine chemicals declined 11% in Swiss franc terms and were flat in local currencies at 975 million francs. Sales of diagnostics were 490 million francs, down 10% in Swiss francs and up 4% in local currencies. Turnover of fragrances and flavors amounted to 521 million francs, down 4% when expressed in Swiss francs and up 7% in local currencies. Turnover from Roche's other products amounted to 34 million francs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight